114
Participants
Start Date
March 1, 2024
Primary Completion Date
February 28, 2027
Study Completion Date
February 28, 2027
low-dose radiation therapy and stereotactic body radiation therapy
Patients will receive radiation therapy.
chemotherapy
Patients will receive sintilimab combined with standard platinum-based doublet chemotherapy for a total of 4 cycles. Patients subsequently received maintenance treatment with sintilimab, and continued treatment until disease progression (PD), intolerable toxicity, withdrawal of informed consent, initiation of other anti-tumor treatments, death, or other circumstances that should stop treatment as specified in the protocol. Whichever occurs first. The maximum treatment time with sintilimab is 24 months (or 35 cycles).
Sintilimab
Patients will receive sintilimab combined with standard platinum-based doublet chemotherapy for a total of 4 cycles. Patients subsequently received maintenance treatment with sintilimab, and continued treatment until disease progression (PD), intolerable toxicity, withdrawal of informed consent, initiation of other anti-tumor treatments, death, or other circumstances that should stop treatment as specified in the protocol. Whichever occurs first. The maximum treatment time with sintilimab is 24 months (or 35 cycles).
RECRUITING
West China Hospital of Sichuan University, Chengdu
Innovent Biologics (Suzhou) Co. Ltd.
INDUSTRY
Sichuan University
OTHER